MannKind | MNKD - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Adma Biologics USD 2.1M 474K 2026-03
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Eli Lilly USD 114.7M 134.3M 2025-09
Halozyme Therapeutics USD 5.59M 80K 2026-06
Insmed USD 18.84M 1.24M 2026-06
Karyopharm Therapeutics USD 12.55M 66K 2026-03
MacroGenics USD 4.89M 1.55M 2026-03
MannKind USD 14.82M 2.38M 2026-06
Merck USD 525M 46M 2026-06
Minerva Neurosciences USD 2.31M 60K 2024-06
Novavax USD 5.82M 342K 2025-12
Pfizer USD 667M 4M 2026-06
Sanofi EUR 287M 109M 2026-06
Xencor USD 7.35M 2.65M 2026-06